Rare diseases
Investigational molecules
Locations
Study of ziftomenib with drug combinations for adults with newly diagnosed acute myeloid leukemia with NPM1 or KMT2A genetic changes
SpainA study to evaluate the safety and effectiveness of tafasitamab in adults with autoimmune thrombocytopenia or autoimmune hemolytic anemia
SpainA study to evaluate the safety and effects of inebilizumab in children and adolescents with immunoglobulin G4-related disease
SpainA study of etentamig and daratumumab compared to daratumumab, lenalidomide, and dexamethasone in adults with newly diagnosed multiple myeloma not eligible for transplant
SpainA study to evaluate the safety and effectiveness of BNT324 and BNT327 in patients with advanced lung cancer
SpainA study comparing the effectiveness and safety of datopotamab deruxtecan and docetaxel in adults with advanced or metastatic non-squamous non-small cell lung cancer
SpainA study to evaluate the long-term safety of apremilast in children with oral ulcers from Behçet’s disease or juvenile psoriatic arthritis
SpainA safety study of romosozumab in children and adolescents with osteogenesis imperfecta
SpainA study to evaluate the long-term safety and effectiveness of mRNA-3927 in patients with Propionic Acidemia
SpainA study of enzomenib in adult patients with relapsed or refractory acute leukemia, including those with MLL rearrangement or NPM1 mutation.
SpainN1T-MC-MALO: A Master Protocol for a Randomized, Controlled, Clinical Trial of Multiple Pharmacologic Agents in Adult Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease Who Are at Increased Risk of Developing Major Adverse Liver Outcomes (SYNERGY-Outcomes); N1T-MC-TZ01 Tirzepatide in participants with high-risk MASLD; N1T-MC-RT01 Retatrutide in participants with high-risk MASLD
SpainEvaluation of Safety, Pharmacokinetics, and Efficacy of RO7782493 and Panitumumab in Advanced Solid Tumors with KRAS G12D Mutation
SpainTell us about your condition – we search every trial in Europe and connect you with the right site.
